<DOC>
	<DOCNO>NCT00002400</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness give HIV-infected patient delavirdine ( DLV ) plus zidovudine ( ZDV ) plus 2 dos indinavir ( IDV ) ZDV plus IDV plus lamivudine ( 3TC ) . This study also examine body process DLV give combination drug .</brief_summary>
	<brief_title>A Study Two Anti-HIV Drug Combinations HIV-Infected Patients</brief_title>
	<detailed_description>In multicenter , open-label study , 45 HIV-1-positive patient receive either combination drug therapy delavirdine ( DLV ) , zidovudine ( ZDV ) , indinavir ( IDV ) combination drug therapy ZDV , lamivudine ( 3TC ) , IDV . NOTE : Patients treat 24 week may opt continue study 24 additional week , HIV-1 RNA le 5,000 copies/ml investigator 's discretion .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 positive . CD4 count 50 . HIV1 RNA great 20,000 . Prior Medication : Allowed : Less 1 month prior treatment zidovudine . Exclusion Criteria Prior Medication : Excluded : Prior 3TC , protease inhibitor , nonnucleoside reverse transcriptase inhibitor . Prior ZDV great 1 month total duration . Prior Treatment : Excluded : Lamivudine . Protease inhibitor . Nonnucleoside reverse transcriptase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>